Financial Summary

Cyclerion Therapeutics Inc  (CYCN)  $2.7    (%)

  • Symbol
    CYCN
    Price
    2.7$
    Beta
    0
    Volume Avrg.
    460967
    Market Cap
    91584544
    Last Div
    0
    Range
    1.69-14.77
    Changes
    -0.03
    Changes Percentage
    Exchange
    NasdaqGS
    Industry
    Biotechnology
    Ceo
    Dr. Peter M. Hecht
    Sector
    Healthcare

About company

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. The company is headquartered in Cambridge, Massachusetts and currently employs 140 full-time employees. The firm is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The firm develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.


Income Statement

Year20192018201720162015201420132012201120102009
Revenue260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess34462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes6393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense3576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses10481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs65737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income55256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics11.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds11.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares3.042.742.432.2121.8211.342.63000
Gross margins0.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.210.220.210.210.230.220.220.270.240.210.19
EBITDA76477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT6393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.210.220.210.210.230.220.220.270.240.210.19